Spotlight Session Information

Spotlight Sessions are thought leadership opportunities at AMCP national meetings offered in 15-minute, 30-minute, 60-minute, and 75-minute timeslots.

Spotlight 15, 30 and 60 theaters are located in the Expo in Hall B. 

Spotlight 75s are located in room 221 on the second floor of the convention center.

Materials presented in theaters may be promotional and concentrate on a specific product, service, or therapeutic area. Therefore, these presentations are considered promotional and do not offer continuing education credit. 


Spotlight Sessions - Tuesday, April 16

10:15–11:30am
Type 1 Diabetes: A Common and Progressive Autoimmune Disease

Room 221
Sponsored by Sanofi
Type 1 Diabetes (T1D) is a progressive autoimmune health condition that affects both children and adults. T1D continues to increase in prevalence worldwide and while there is currently no cure, the importance of early recognition of disease risks and appropriate monitoring can help reduce the risk of severe complications such as DKA (diabetic ketoacidosis) at time of diagnosis as well as the associated potential micro- and macrovascular complications. Recent updates to the ADA Standard of Care guidelines have highlighted the challenges and opportunities for screening, staging, monitoring, diagnosis, and treating patients with T1D. As such, there is a need for greater collaboration among healthcare teams that play a critical role in shaping the direction and strategy of their organizations particularly in relation to T1D treatment pathways.

11:15–11:45am 
Beyond PDTs: The Emerging Role of Non-Prescription Digital Therapeutics in Health

Theater 2, Expo Hall
Sponsored by Sanofi
Are Digital Therapeutics here to stay? What role do they have in the future of care management? Join digital health thought leaders for a 'fireside chat' discussing the landscape and assessment of non-prescription digital therapeutics.

  • Andy Molnar, CEO, Digital Therapeutics Alliance
  • Joe Honcz, RPH, MBA
11:45am-Noon
Uncontrolled Hypertension and Aprocitentan

Theater 1, Expo Hall
Sponsored by Idorsia

12:30–1pm 
PAH Journey: A Patient, Health Care Professional Story

Theater 2, Expo Hall
Sponsored by PHA
Pulmonary arterial hypertension is a complex, life-threatening disease characterized by high blood pressure in the lungs. In this unique session, a PAH patient and an expert health care professional share their PAH journey and their insights on the impact of effective management on this life-altering condition.

  • Tonya Zeiger, RRT, CPFT
  • Gerry Langan
12:45–1pm
Enabling frictionless patient access to optimal treatment through responsible use of AI   

Theater 1, Expo Hall
Sponsored by Klick Health 

3–4pm
Spotlight Session Sponsored by Boehringer Ingelheim

Theater 3, Expo Hall
Sponsored by Boehringer Ingelheim

3–4pm
From LDL to Lp(a): Opportunities to Reduce the Rising Tide of Cardiovascular Disease   

Theater 4, Expo Hall
Sponsored by Family Heart Foundation

3:30-4pm
The Real-world evidence on Mavenclad

Theater 2, Expo Hall
Sponsored by EMD Serono

3:45pm–4pm

Bridging the Divide Between Payers and PBMs with Payment Integrity Solutions

Theater 1, Expo Hall
Sponsored by HealthPlan Data Solutions
Bridging the divide between payers and PBMs with payment integrity solutions. HDS is a software company that leverages cutting edge technology and industry expertise to drive out over-spend and deficiencies in contract compliance. HDS uses our technology to identify savings opportunities and areas where plan design has not been implemented appropriately to drive cost-savings and claims accuracy. Our emphasis on data-driven accuracy supports better outcomes for payers, PBMs, and their members. In this Spotlight 15 session, HDS will provide an overview of its ongoing pharmacy claims monitoring product, Claim Scan, and review real examples of realized customer savings driven in managed care.
  • Sterling Harpst, PharmD

Spotlight Sessions - Wednesday, April 17 

9:45am-11am
Preparing for PDTs: Operational Readiness for Covering Digital Therapeutics

Room 221
Sponsored by Boerhinger-Ingelheim

Join us for a moderated panel discussion on operational readiness for coverage of prescription digital therapeutics (PDTs). As a new modality of treatment, PDTs have unique considerations for coverage. This discussion will examine what changes are needed to create a robust coverage framework. Panelists will be from the health payer industry and PDT development and manufacturing industry.  

10:45am-11:45am
ATTR Amyloidosis Cardiomyopathy - Disease State Overview 

Theater 2, Expo Hall
Sponsored by Alnylam

11:30am–12:30pm
MASH Unveiled: Understanding the Disease Burden 

Theater 3, Expo Hall
Sponsored by Novo Nordisk
Join us to learn about MASH, or metabolic dysfunction-associated steatohepatitis (previously NASH, or nonalcoholic steatohepatitis), its prevalence, diagnosis, and potential consequences. Discover the economic burden, non-invasive risk stratification, and how the FIB-4 index can be used as a cost predictor. Learn how patients can benefit from a multidisciplinary approach to manage MASH.

  • Dr. Mazen Noureddin, MD, MHSc
11:30am–12:30pm 
Beyond The Surface of Duchenne: Contextualizing Evolving Functional Outcome Measures   

Theater 4, Expo Hall
Sponsored by Sarepta Therapeutics
Join Sarepta Therapeutics for a presentation on different functional assessments used for measuring disease progression in patients with Duchenne muscular dystrophy within clinical trials and in the clinical practice setting.

  • Armen Khachatourian, PharmD, MBA, HEOR, Director, Medical Managed Care, Sarepta Therapeutics
  • Kristen Ricchetti-Masterson, PhD, MSPH, Senior Director, Real World Evidence, Sarepta Therapeutics
11:45am–12pm
Overview of Zurzuvae for Post-Partum Depression

Theater 1, Expo Hall
Sponsored by Sage Therapeutics and Biogen
Presentation to include an overview of prescribing information, indication, dosing and administration, and safety information.

  • Gary Owens, MD
12–12:30pm 
Overview of Zurzuvae for Post-Partum Depression

Theater 2, Expo Hall
Sponsored by Sage Therapeutics and Biogen
Presentation to to include disease state awareness (prevalence, symptoms, etc)prescribing information, indication, dosing and administration, safety information, and overview of clinical development program

12:45–1:15pm
A Targeted Approach to the Treatment of Nonsegmental Vitiligo

Theater 2, Expo Hall
Sponsored by Incyte

1:30–2pm
HEMGENIX® (etranacogene dezaparvovec-drlb) at 3 Years  

Theater 2, Expo Hall
Sponsored by CSL Behring

1:30–2:30pm
Adbry, a targeted IL-13 inhibitor for moderate-to-severe atopic dermatitis   

Theater 3, Expo Hall
Sponsored by LEO Pharma

1:30–2:30pm

VEOZAH (fezolinetant) for the treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause

Theater 4, Expo Hall
Sponsored by Astellas

1:45–2pm
Q&A Session on IVIG Therapy and Patient Access   

Theater 1, Expo Hall
Sponsored by Octopharma

PIE LogoScience & Innovation Theaters with a PIE logo include preapproval information exchange information. In accordance with federal laws and regulations, attendance at these sessions is restricted to payors, formulary committees, or other similar entity representatives with knowledge and expertise in health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. Look for additional details on the PIE information page

Additional Spotlight Session sponsorship opportunities may be available. Contact Kim Spear, senior director of business strategies, at kspear@amcp.org for more details.